Trials / Unknown
UnknownNCT00297570
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
- Status
- Unknown
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Sheba Medical Center · Other Government
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is controlled and randomized in Philadelphia-positive chronic myeloid leukemia (Ph+ CML) patients with complete cytogenetic response after more than one year of imatinib therapy. The aim is to explore a possible benefit in the addition of peg-interferon (Peg-IFN) to imatinib, in terms of the rate of achievement, molecular remission, and response duration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pegylated Interferon and Imatinib |
Timeline
- Start date
- 2006-02-01
- First posted
- 2006-02-28
- Last updated
- 2007-10-10
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00297570. Inclusion in this directory is not an endorsement.